Banco Bilbao Vizcaya Argentaria S.A. Grows Position in Biogen Inc. $BIIB

Banco Bilbao Vizcaya Argentaria S.A. raised its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 6.0% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 146,951 shares of the biotechnology company’s stock after purchasing an additional 8,297 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Biogen were worth $25,863,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of BIIB. Norges Bank purchased a new position in shares of Biogen during the 4th quarter valued at about $464,408,000. Boston Partners bought a new stake in Biogen during the 4th quarter worth approximately $302,815,000. Fred Alger Management LLC lifted its holdings in Biogen by 39,074.8% during the fourth quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after purchasing an additional 796,735 shares in the last quarter. Orion Porfolio Solutions LLC boosted its position in shares of Biogen by 6,828.4% in the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after purchasing an additional 509,809 shares during the period. Finally, Caisse de depot et placement du Quebec increased its stake in shares of Biogen by 718.2% in the third quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock worth $79,741,000 after purchasing an additional 499,676 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

NASDAQ BIIB opened at $198.67 on Thursday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97. The business has a 50 day simple moving average of $190.05 and a two-hundred day simple moving average of $184.70. The stock has a market capitalization of $29.33 billion, a PE ratio of 21.32 and a beta of 0.20.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the prior year, the company earned $3.02 EPS. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, research analysts predict that Biogen Inc. will post 13.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Evercore initiated coverage on shares of Biogen in a report on Friday, May 15th. They issued an “outperform” rating for the company. Morgan Stanley boosted their price objective on Biogen from $200.00 to $206.00 and gave the company an “equal weight” rating in a research report on Thursday, April 30th. Wall Street Zen raised Biogen from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Mizuho cut their price objective on shares of Biogen from $236.00 to $221.00 and set an “outperform” rating for the company in a report on Monday. Finally, Freedom Capital raised shares of Biogen from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $216.70.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.